Healthcare stocks are mixed this afternoon, with the NYSE
Healthcare Sector Index slipping about 0.2% while shares of
healthcare companies in the S&P 500 are down about 0.3 as a
In company news, Thoratec (
) is ahead by more than 9% at $42.98, drifting slightly under its
new 52-week high of $43.33 that followed the maker of implantable
heart pumps' posting Q3 EPS of $0.49, ex one-time items, beating
analyst estimates by $0.09.
Revenue rose 7.3% year over year to $126.4 million, also
exceeding the Capital IQ average call of analysts by $5.1
THOR raised its FY13 earnings guidance, now forecasting EPS of
between $1.85 to $1.90, ex special items, up from its previous
outlook expecting $1.69 to $1.79 per share. It narrowed its revenue
forecast, however, now predicting between $500 million to $505
million in quarterly revenue - in from its prior guidance for $490
million to $510 million.
Analysts, on average, are looking for THOR to earn $1.75 per
share on $502.45 million in revenue.
Following the improved results and outlook, analysts at
Barrington Research reiterated their Outperform rating for THOR
shares, increasing its price target by $9 to $49 a share.
In other sector news,
(+) ZLTQ, (+39.6%) Posts $0.08 per share net loss, easily
beating the $0.19 per share loss analysts expected. Doubles FY13
revenue guidance to 40% year over year increase, which would be
$106.7 mln, topping estimates by $14.2 mln.
(-) ARIA, (-42.2%) Temporarily shelves its Iclusig leukemia
treatment because of possible cardiac-related side effects linked
to the drug.